Development and evaluation of women centric comprehensive weight management module

Department of science and technology DST0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年3月6日

试验速览

暂无简介。

•Group A: Postpartum women
•i. Women aged between 25-35 years.
•ii. Women in the postpartum period from 6 weeks to 6 months post-delivery, after
•37 week pregnancy term through a normal or C-section delivery.
•iii. Women who gave singleton birth.
•iv. BMI between >= 25 to <=39.9kg/m2.
•v. Women who can provide a history of pre-pregnancy weight and gestational
•weight gain (3, 6 and 9 months) as medical record or recall.
•vi. Women who can read in Hindi/ English.
•vii. Women who will be lactating.
•Group B: Perimenopausal women
•i. Menopausal women aged between 40-55 years.
•ii. Women with an intact uterus, >= 1 functioning ovary and >=1 menstrual period in past 12
•iii. BMI between >= 26 to <=39.9kg/m2.
•iv. Women who can read in Hindi/ English.
•v. Intend to follow up regularly will be included in the study.
•vi. The ownership or accessibility to mobile phones for technology based intervention.

•Group A: Postpartum women
•i) Women with pregnancy related complications (pre-eclampsia, pre-term, hemorrhage, infection).
•ii) Patients with secondary causes of obesity (like Hypothyroidism, Cushingâ??s
•diseases, PCOS).
•iii) Acute infections, advanced end-organ damage or chronic diseases: renal/ hepatic
•failure, any malignancy
•iv) Current intake of medicine known to affect body weight such as drugs acting on
•the central nervous system, cathartics, thyroid supplements, diuretics and selective
•serotonin reuptake inhibitors.
•v) Psychosocial contraindications such as bulimia nervosa, anorexia nervosa,
•substance abuse, clinically significant depression or under current psychiatric
•Group B: Perimenopausal women
•i. Women using oral or injectable hormonal contraception, tamoxifen, tibolone and
•raloxifene in the previous 3 months.
•ii. Patients with secondary causes of obesity (like Hypothyroidism, Cushingâ??s diseases,
•iii. Acute infections, advanced end-organ damage or chronic diseases: renal/ hepatic failure,
•any malignancy.
•iv. Current intake of medicine known to affect body weight such as drugs acting on the
•central nervous system, cathartics, thyroid supplements, diuretics and selective serotonin
•reuptake inhibitors.
•v.Psychosocial contraindications such as bulimia nervosa, anorexia nervosa, substance abuse, clinically significant depression or under current psychiatric care.
•vi. Planning to move out within the study period

发起方

Department of science and technology DST